SI-BONE

Historical price data

SI-BONE is a leader in developing and commercializing minimally invasive solutions for sacroiliac joint dysfunction, a condition implicated in 15-30% of chronic low back pain cases. Founded in 2009, the company has established a robust clinical foundation for its iFuse Implant System, including multiple randomized controlled trials and over a hundred peer-reviewed publications. As a publicly traded entity, SI-BONE continues to invest in clinical research and expand its product portfolio to solidify its market position and address adjacent indications like pelvic trauma and spinopelvic fixation.

The iFuse Technology platform centers on minimally invasive surgical implants, primarily a patented triangular titanium design, for stabilizing and fusing the sacroiliac joint to relieve pain.

1 drug in pipeline

SI-BONE competes with other minimally invasive SI joint fusion devices from companies like Medtronic, Globus Medical, and Zyga Technology. Its primary differentiation is its extensive clinical evidence base, including Level I RCT data, a patented triangular implant design, and a large installed base of trained surgeons.